Cancer Research in HKUMed
1. Central Nervous System


  • 1.1.Clinical Trial
    • 1.1.1.Brain

1.0 Central Nervous System

1.1 Clinical Trial

1.1.1 Brain: Recurrent High-Grade Glioma

Specific Selection Criteria: DDRd, IDH, PTEN, BRCAness

Second-line treatment: Phase 2

Targeted therapy (PARP Inhibitor), Chemotherapy

Study Title

Main Inclusion/Exclusion

Investigational Product

Principal Investigator

Department

Email

Contact number

Combination Talazoparib - carboplatin for recurrent high-grade glioma with DNA damage repair deficiency (DDRd) “TAC-GReD” trial.

Key Inclusion Criteria:

  1. Recurrent high grade glioma with DDRd, defined by genomic aberrations associated including IDH mutation, PTEN mutation and “BRCAness” signature (ATM, ATR, BAP1, BRCA1, BRCA2, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, PALB2, NGS1, WRN, RAD50, RAD51B, RAD51C, RAD51D, MRE11A, BLM, BRIP1).

Talazoparib (PARP inhibitor) + Carboplatin (Chemo)

Dr. Aya El Helali

Department of Clinical Oncology

 

ahelali@hku.hk

Stephen AU

2255 5034